Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more
Percheron Therapeutics Limited (PERCF) - Total Liabilities
Latest total liabilities as of June 2025: $2.43 Million USD
Based on the latest financial reports, Percheron Therapeutics Limited (PERCF) has total liabilities worth $2.43 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Percheron Therapeutics Limited - Total Liabilities Trend (2022–2025)
This chart illustrates how Percheron Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Percheron Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Percheron Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yggdrazil Group Public Company Limited
BK:YGG
|
Thailand | ฿43.86 Million |
|
Pioneer Embroideries Limited
NSE:PIONEEREMB
|
India | ₹1.63 Billion |
|
Megapower Makmur TBK PT
JK:MPOW
|
Indonesia | Rp38.61 Billion |
|
Solargiga Energy Holdings Limited
PINK:SEHLF
|
USA | $2.17 Billion |
|
Meta Epsi Tbk PT
JK:MTPS
|
Indonesia | Rp31.10 Billion |
|
Upco International Inc
PINK:UCCPF
|
USA | $563.42K |
|
Equinox Resources Ltd
AU:EQN
|
Australia | AU$161.37K |
Liability Composition Analysis (2022–2025)
This chart breaks down Percheron Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Percheron Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Percheron Therapeutics Limited (2022–2025)
The table below shows the annual total liabilities of Percheron Therapeutics Limited from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $2.43 Million | -52.93% |
| 2024-06-30 | $5.17 Million | +80.21% |
| 2023-06-30 | $2.87 Million | +121.38% |
| 2022-06-30 | $1.30 Million | -- |